Talk:APW-EDM White Paper

Discussion Page for APW-EDM White Paper

NOTE FROM NCJ: Per Gunter's suggestion, I made the discussion page, and I'm moving a lot of my comments/questions that I had written in text over to here. Hopefully that will make the main page for drafting the white paper less messy and more readable. -Nicholas C. Jones (talk) 15:24, 13 March 2018 (CDT)

Discussion: Use Case #1: Image Slides for Secondary Review / Consultation

Regarding 1c: NOTE FROM NCJ: Dr. Dash: can you verify that we should separate this out from 1b or should we put it as a sub-category under 1b, since the physician here is going to get pt consent for the consultation anyways? In my experience though, these are of noteworthy difference both in clinical processes and in likelihood of impact /avg value from 1b. -Nicholas C. Jones (talk) 15:24, 13 March 2018 (CDT)

Regarding time frames for returning glass slides: (NOTE FROM NCJ: In the US, the norm is 30 days, though I believe this is a norm rather than a law. Are there differences in practice in Europe and other areas of the world?) -Nicholas C. Jones (talk) 15:24, 13 March 2018 (CDT)

Regarding 1e: NOTE FROM NCJ: I am not familiar enough with these processes to go into depth here. It's even worth questioning that we want this in the profile, as it's only semi-clinical. But I think there's at least benefit in mentioning that this is something to consider for system and workflow design so the vendors are at least aware of this as a different use case. What do the rest of the white paper team think? -Nicholas C. Jones (talk) 15:24, 13 March 2018 (CDT)

NOTE FROM NCJ: Hopefully between the contexts listed above, the consultation contexts ppt & discussion in the teleconference, and future discussion, we can all get to the same page on why these contexts have significant differences in workflow. The big question to me is do we want to make 1 big decision tree profile for all consultation, different trees for different contexts, or do the other authors have other suggestions? I must note that this is a big area where there is a gap in functionality for many vendor products, because these nuances have not been explained in white paper form previously. So while we might recoil from the complexity here, I think this is a key area of value of the white paper, but I am open to constructive criticism here. -Nicholas C. Jones (talk) 15:12, 13 March 2018 (CDT)

Discussion: Use Case #7: Quality Control / Quality Assurance and Error Correction Workflows to Support Digital Pathology

NCJ Note: Quality control and quality assurance are somewhat polysemous terms. See my ppt from shared dropbox area for some details. For clarity here, I will define 3 terms for use within the document. We can debate these if desired.

Definitions: Quality Evaluation (QE): An assessment from a device, software algorithm, or person about the quality of a target physical or digital asset. NCJ Note: My definition here, just to make the distinction between the common vernacular of QC - as in "he QC'd the image" versus the formal definition of quality control. I'm open to using a different phrase if desired. But an important distinction here is that the scanners and scanning software have internal QE tools, which we would want to discriminate from technician QE, pathologist QE, and potential external algorithmic analytic QEs. Note that the scanner/software/tech QEs have been part of both FDA clinical validations and technical validations. (See FDA technical guidance. Quality Control (QC): A system for verifying and maintaining a desired level of quality in an individual test or process. (From traditional CAP definition. My note: usually implies prospective processes, and to generate data.) Quality Assurance (QA): Systemic monitoring of quality control results and quality practice parameters to assure that all systems are functioning in a manner appropriate to excellence in health care delivery. (From traditional CAP definition.) -Nicholas C. Jones (talk) 17:53, 13 March 2018 (CDT)

Discussion: Use Case #10: Image Registration Functions

Regarding 10.c: NOTE FROM NCJ: Does anyone know of any groups using image registration from WSIs/blocks to gross images in a clinical environment? If so, we should separate that out from the "future use" section.) -Nicholas C. Jones (talk) 15:24, 13 March 2018 (CDT)

Discussion: Use Case #11: Digital Pathology in Support of Intraoperative Procedures

I think we could batch frozen section interpretations and rapid FNA adequacy assessments here together, but it anyone wants to split them into different use cases, that would be fine as well. -Nicholas C. Jones (talk) 15:24, 13 March 2018 (CDT)